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The Thrombolysis in Myocardial Infarction (TIMI) Study
Group is investigating whether percutaneous translu-
minal coronary angioplasty or intravenous beta-receptor
blockers, or both, are useful adjuncts to recombinant
tissue-type plasminogen activator (rt-Pa) in the treat-
ment of patients with acute myocardial infarction (TIMI
II study). A total of 317 patients with acute myocardial
infarction were treated an average of 2.7 hours after the
onset of chest pain during the course of a nonrandomized
pilot investigation with 150 mg of rt-PA given over 6
hours. This dose of rt-PA resulted in a high rate of
infarct-related coronary artery patency (82 and 87% of
patients catheterized an average of either I or 32 hours
Coronary artery disease is the leading cause of death in the
United States; each year approximately 540,000 individuals
die of this disorder (I). Acute myocardial infarction results
in the hospitalization of approximately 750,000 patients each
year (2). This syndrome is produced by interruption of re-
gional coronary blood flow, and ischemic myocardial ne-
crosis is the result. Necrosis and its sequelae (ventricular
arrhythmia, congestive heart failure and cardiac rupture)
cause death during hospitalization in 10 to 15(fc, of hospi-
talized patients. Furthermore, patients with infarct-scarred
myocardium are at increased risk of sudden death and
congestive heart failure after hospital discharge. The risks
~A list of TlMI investigators appears in Appendix I.
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after entry, respectively) and a low 21 day mortality rate
of 4.4%.
Coronary angioplasty was performed successfully in
>90% of patients with appropriate anatomy and in >50%
ofthose treated with rt-PA. In 75 patients treated within
2 hours of the onset of chest pain only 2 (2.7%) were
dead by 6 weeks. However, five cases of intracranial
hemorrhage were noted, and the rt-PA dose was sub-
sequently reduced to 100 mg given over 6 hours. The
TlMI II design and the results of the TIMl II pilot stud}'
are discussed.
(J Am Coli CardioI1987;JO:5JB-64B)
of unfavorable outcome are directly related to infarct size
(3).
Application of coronary arteriography to patients in the
early hours of infarction has resulted in a better understand-
ing of coronary pathophysiology in patients with myocardial
infarction (4-6). About 80% of patients with >30 minutes
of chest pain associated with ST segment elevation have an
occlusive coronary thrombus superimposed on an athero-
sclerotic plaque (7). It appears that the direct cause of in-
farction in these patients is the formation of occlusive throm-
bus, a finding with substantial implications both for prevention
of infarction and for interruption of the infarction process
by various reperfusion strategies applied singly or in con-
cert.
A rcperfusion strategy that can be quickly and generally
applied is the intravenous administration of thrombolytic
agents. There is evidence from a number of clinical trials
(S-ll and unpublished data) that streptokinase, an agent of
moderate coronary reperfusion efficacy when given intra-
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venously, results in a 15 to 20% reduction in 21 day mor-
tality. Although it is clear that early administrationof throm-
bolytic therapy has clinically important effects on subsequent
mortality in patients with acute myocardial infarction and
may be particularly effective in some subgroups, such as
patients with anterior infarction and those treated soon after
the onset of symptoms (9), a number of questions remain
regarding the choice of thrombolytic agent and the use of
adjuncts to thrombolytic therapy.
A new generation of more fibrin-specific thrombolytic
agents offer improved reperfusion rates and, at least in prin-
ciple, a greater potential for reduction in subsequent mor-
bidity and mortality. An endogenous thrombolytic agent,
tissue plasminogen activator (rt-PA), is now available in
clinically useful quantities because of successful production
by meansof recombinant DNA techniques. Two multicenter
trial groups (12,13) have performed direct randomizedcom-
parisons of intravenous rt-PA and streptokinase using ar-
teriographically demonstrated patency of the infarct-related
artery as the primary outcome measure. In both trials (12,13),
investigators observed that intravenous rt-PA was more ef-
fective than intravenous streptokinase and that rt-PA achieved
rcperfusion rates approaching those previously reported with
intracoronary administration' of streptokinase.
The Thrombolysis in Myocardial Infarction (TIMl) Study
Group ",'as established by the National Heart, Lung, and
Blood Institute in 1983. The TIMI Study Group has com-
pleted a series of investigations including: I) Open label
studies of rtcPA and streptokinase done as a prelude to TIMI
1(14,15). 2) TlMI 1. a randomized comparison of rt-PA
and streptokinase using arteriographically documented es-
tablishment of perfusion in closed infarct-related arteries as
the primary end point (12, 16-18). 3) Open label studies
(19) with a series of increasing doses to evaluate a new
formulation of rt·PA and exploration of the feasibility of
performing percutaneous transluminal coronary angioplasty
in the same series of patients used to determine optimal dose
of the new rt·PA formulation as reported elsewhere in this
supplement by Williams et al. (20).
TIMI Il, a randomized study designed to determine the
utility of two adjuncts to thrombolytic therapy, coronary
angioplasty and immediate administration of intravenous
beta-receptor blockers, was begun in 1986. Because TlMI
II is a complex study, a pilot study was undertaken to de-
termine feasibility. The design of TIMI Il and the TIMI Il
pilot study and the results of the pilot investigation are
presented in this article.
Methods
The TIMl /I Study
The TIMI Study Group (Appendix I) was expanded in
1986 and now includes 50 hospitals under the direction of
24 TIM) Principal Investigators. Central units include a data
coordinating center, a drug distribution center and core lab-
oratories established to provide standardized assessment of
electrocardiographic (ECG), radiographic, radionuclide, co-
agulation and postmortem studies. The principal objective
of the TIMI rr trial is to determine whether coronary an-
gioplasty is a useful adjunct to rt-PA in patients with myo-
cardial infarction. Two subtrials, IIA and lIB, are designed
to evaluate the timing of coronary angioplasty and the con-
comitant use of immediate intravenous beta-receptor blocker
therapy, respectively. Patient recruitment for TIMI rrA is
performed at 7 clinical units; patient recruitment for lIB is
carried out at 43 clinical units.
TIM} 11 Protocol
Selection of patients. Eligible patients are those with
;:::30 minutes of chest discomfort associated with >-0.1 mV
of ST segment elevation in at least two contiguous electro-
cardiographic (ECG) leads. Patients must be treated within
4 hours of the onset of chest pain. Patients with one or more
of the following are excluded: lack of informed consent.
interval > 4 hours from the onset of pain, unknown time of
onset of pain. age > 75 years, uncontrolled hypertension
(> 1801110 mm Hg), history of a cerebrovascular event.
active hemorrhage or hemorrhagic diathesis, left bundle branch
block, prior cardiac surgery, prolonged cardiopulmonary
resuscitation or major surgical procedure within 2 weeks,
dilated (congestive) cardiomyopathy, oral anticoagulant
therapy, psychological or physical inability to participate,
known advanced illness and women of childbearing poten-
tial.
Treatment protocol. Patients entering the 11M! II trial
are treated within the following general guidelines: All pa-
tients receive a 6 hour infusion of rt-PA and are randomly
assigned to coronary angioplasty at 18 to 48 hours after
entry, to no angioplasty or, in the lIA subtrial only, to
immediate angioplasty. Continuous intravenous heparin at
1,000 units/h is begun I hour after an initial 5,000 unit
bolus given at the initiation of the rt-PA infusion. The hep-
arin infusion is adjusted to maintain an activated partial
thromboplastintime between 1.5 and 2 times the upper limit
of normal and, in the absence of hemorrhage, is continued
until the fifth hospital day. Additional conventional treat-
ment includes administration of intravenous lidocaine for a
minimum of 24 hours as well as oxygen and opiates as
needed. Aspirin, 80 mg/day. is begunon day 2 and increased
at the termination of heparin on day 5 to 325 mg/day. TIMI
patients are monitored carefully for the first several days in
a coronary care unit with particularattention to identification
of complications of myocardial infarction such as shock,
ventricular fibrillation. reinfarction, angina and heart fail-
ure. Vascular puncture sites are cared for meticulously, and
the occurrence of bleeding is noted. Blood is drawn at entry.
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at 50 minutes and at 5 and ~ hours after initiation of rt-PA
for central laboratory determination of a variety of clotting
factor concentrations and activities. Recurrent myocardial
infarction is diagnosed by clinic investigators when the pa-
tient experiences prolonged chest pain with characteristic
ECG and cardiac enzyme changes. Recurrent myocardial
infarction is confirmed by an independent morbidity and
mortality subcommittee unaware of treatment assignment.
Predischarge evaluation. During predischarge evalua-
tion, after autologous red blood cell labeling with tcchne-
tium-99m and rest radionuclide ventriculography, supine
patients are exercised with a bicycle ergometer to a heart
rate limitof l20/min or a maximal work loadof 400 kpm/rnin.
Findings during or after exercise including 2:0.2 mY hor-
izontal ST segment depression, reduction of 20 mm Hg in
systolic blood pressure, reduction of ejection fraction of 5
or more on ventriculography. angina pectoris or complex
ventricular arrhythmias provide evidence of myocardial
ischemia. Coronary arteriography is recommended in pa-
tients with one or more of these indicators of active ischemia
and in those with uncontrolled angina regardless of treatment
assignment; subsequent application of coronary angioplasty
or coronary artery bypass graft surgery is governed by the
specific findings in the individual case. At 6 weeks a max-
imal bicycle exercise radionuclide ventriculogram is per-
formed. Radionuclide ventriculographic studies are evalu-
ated both by TIMI clinical units and by the TIMI central
radionuclide laboratory for both global and regional func-
Figure 1. TIMI II design including 7 TIMI IIA centers and 4.~
TIMI lIB centers. BB = beta-blocker therapy; IV - intravenous:
PTCA = percutaneous transluminal coronary angioplasty: rt-PA =
recombinant tissue-type plasminogen activator.
II A CENTERS
rl-PA TREATED
~
2 HR PTCA 18-48 HR PTCA NO PTCA
II B CENTERS
rl-PA TREATED
.r<:
NOT ELIGIBLE FOR ELIGIBLE FOR
IMMEDIATE BB IMMEDIATE BB
-. '0'A"
18-48 HR NO 18-48 HR NO 18-48 HR NO
PTCA PTCA PTCA PTCA PTCA PTCA
Table 1. TIMI II Trial: Contraindications to
Coronary Angioplasty
Infarct-related wronary lesion results in <60'h reduction in luminal
diameter
2. Lexion is technically very difficult or imposxihk; including:
Length ",20 mrn
Involves major coronary hilurcution
Distal
Beyond a tortuous proximal vessel
3. Lesion is pari of a very compromised coronary circulation such that
angioplasty complication would be catastrophic including:
Left main coronary lesion> 7OCl<
Infarct-related lesion providing substantial fraction of remaining
coronary flow
tion. Additional patient evaluations arc scheduled at 6 months
and I year after entry; patients are followed up by telephone
contact at 6 month intervals thereafter.
TIM! IlA: Special Features
Patients entered into the TIM] llA study (Fig. 1) arc
randomly assigned I) to immediate coronary arteriography
followed by coronary angioplasty if the infarct-related lesion
is technically approachable, 2) to coronary arteriography
followed by angioplasty. if possible, !8 to 4R hours after
the start of rt-PA or 3) to no angioplasty unless severe
recurrent ischemic symptoms or unequivocal evidence of
ischemia is noted during predischarge exercise radionuclide
ventriculography.
AngiopIasty protocol. Patients randomized to the im-
mediate coronary angioplasty group arc taken to the cardiac
catheterization laboratory as soon as possible and angio-
plasty is performed < 120 minutes after the start of the rt-
P1\ infusion. Careful placement of an arterial sheath is fol-
lowed by left ventriculography in the right anterior oblique
projection. A standardized arteriographic protocol requires
that the suspected infarct-related artery be injected last. The
advisability of proceeding with angioplasty is assessed im-
mediately and it is performed if possible. Patients assigned
to 18 to 48 hour coronary angioplasty undergo left ventric-
ulography and coronary arteriography during this I to 2 day
interval and angioplasty is performed if possible. Angie-
plasty is restricted to the coronary lesion or lesions thought
responsible for the infarction and is limited by certain prac-
tical considerations. Thus, for patients in the immediate
angioplasty group, dilation of the infarct-related lesion is
not attempted (Table I) in the following circumstances:
lesions with <60O/C stenosis in coronary luminal diameter;
lesions that are technically unsuitable; or lesions that would
result in life-threatening hemodynamic instability in the event
of occlusion. Additional prohibitions to dilation in patients
in the I~ to 48 hour coronary angioplasty group are total
occlusion of the presumed infarct lesion and preemption by
a prior procedure or complication.
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Definitions of perfusion improvement. Standardized
definitions regarding the degree of improvement in lesion
severity afforded by coronary angioplasty are displayed in
Table 2. Full improvement requires normal or improved
flow and both an absolute reduction in luminal stenosis by
:::: 20% and a final luminal stenosis < 60%. Partial improve-
ment requires unchanged or improved flow and only one of
the anatomic improvements. Full. partial and no improve-
ment are assessed by both the clinic and radiographic core
laboratory on the basis of the last injections of the infarct-
related artery at the completion of coronary angioplasty.
Clinical complications such as death. myocardial infarction
or need for emergency coronary artery bypass graft surgery
that occur in the next 24 hours are subtractedfrom the crude
improvement rate, resulting in a rate summarizing improve-
ment free of immediate complications.
Predischarge coronary arteriography and ventricu-
lography. All patients participating in TIMI I1A are sched-
uled for predischarge coronary arteriography and left ven-
triculography to assess patency of the infarct-related artery
and to determine rest global and regional left ventricular
function . Rest global left ventricular ejection fraction de-
termined radiographically is the primary end point for the
comparison of immediate«2 hour), delayed(18 to 48 hour)
and indefinitely deferred coronary angioplasty (no angio-
plasty unless clinically indicated) groups and is assessed by
the TIMI radiographic core laboratory by previously re-
ported techniques without knowledge of clinical details or
therapeutic assignment (21). Regional ventricular function
and arterial patency at hospital discharge are also assessed
by the central laboratory(22-25) . Additional important out-
come measures assessed in both the clinic and radiographic
core laboratory include arterial patency and left ventricular
function determined by cardiac catheterization as soon as
possible after the start of rt-PA infusion in the patients
Table 2. TIM! II Coronary Angioplasty Outcome
I . Full improvement is present when the postd ilation arteriogram dern-
onstrates:
Flow thaI is TIM I perfusion grade ] or improved from grade 0 or I
III grade 1
and
Decreas e in luminal stenosis ~10% (for example. 70 to 50%)
and
Luminal steno sis of < 60%
2. Partial improvement is present when the postdilation arteriogram dem-
onstrates:
Flow that is Tl~t1 perfusion grade 3 or TIM) perfusion grade improves
from grade 0 or ) to grade 2 or 3 or from grade 2 to grade 3
and
Luminal stenosis is decreased by ~20% or luminal stenosis is <:6{)%
or
Flow remains at TIMI perfusion grade 2
and
Luminal stenosis is improved by ~20%
assigned to immediate coronary angioplasty and in patients
studied 18 to 48 hours after initiation of rt-PA infusion.
Coronary perfusion status is graded at both the clinic and
the central radiographic laboratory according to previously
published TIMI criteria: Grade 0 indicates no flow; Grade
I. penetration without perfusion; Grade 2, full perfusion
with slow flow: and Grade 3. full perfusion with normal
flow (12).
Lack of adherence to treatment assignment. TIMI II
patients assigned to immediate or delayed coronary angio-
plasty do not invariably undergo the procedure. This lack
of adherenceto treatment assignment is due largely to coro-
nary artery obstruction that is either too mild or too severe
for safe application of current angioplasty techniques. In
addition, it is anticipated that a small number of patients
assigned to no angioplasty will undergo coronary angio-
plasty or bypass graft surgery. For purposes of analysis.
patients assigned to immediatecoronary angioplasty are re-
tained in this group even though some will not have been
treated with angioplasty. The same analysis by intention to
treat is planned for patients in the 18to 48 hour angioplasty
group and for the indefinitely deferred angioplasty group.
TIMl //8: Special Features
Selection of patients for beta-blocker therapy. In ad-
dition to contributing data for examination of the overall
TlMI II question of whether coronary angioplasty at 18 to
48 hours is a useful adjunct to thrombolytic therapy, the
TIMllIB study is designed to assess the effect of immediate
intravenous beta-receptor blocker therapy in those deemed
capableof tolerating it (Fig. I). Eligible consenting patients
entering the trial but excluded from the beta blocker study
are those on long-term maintenance therapy with a beta-
receptor blocker. verapamil or diltiazern, and those with
relative contraindications to intravenous beta-blockers in-
cluding a ventricular rate of < 55 beats/min, systolic blood
pressure < 90 mm Hg, moist rales over the lower one-third
of the lung fields. advanced atrioventricular block and a
history of asthma. These patients who are not candidates
for intravenous beta-blockertherapy are randomly assigned
to cardiac catheterization 18 to 48 hours after the start of
rt-PA followed by coronary angioplasty or to indefinitely
deferred angioplasty.
Randomization of patients. In patients not taking a
beta-blocker. verapamil or diltiazem with no contraindica-
tions to immediate intravenous beta-blocker therapy. ran-
domization is carried out in a factorial design to coronary
angioplasty at 18 to 48 hours or indefinitely deferred an-
gioplasty and to immediate intravenous beta-blockade with
metoprolol or deferred metoprolol . In those randomized to
immediate parenteral beta-blocker therapy, 15 mg of me-
toprolol is given in three 5 mg injectionsspaced at 2 minute
intervals followed by oral rnetoprolol, 50 mg twice a day,
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during the first hospital day and 100 mg twice a day there-
after. Those assigned to deferred beta-blocker therapy are
begun on oral metoprolol before hospital discharge. The
primary means of assessing the effect of immediate intra-
venous metoprolol compared with deferred oral metoprolol
is rest left ventricular ejection fraction determined by pre-
discharge radionuclide ventriculography.
TIM/II: End Points
The primary end point of the TIMI II trial is survival
free of recurrent myocardial infarction to 6 weeks. 1\ variety
of secondary end points have been declared, including mor-
tality free of recurrent infarction at 6 months and I year and
total mortality at 6 weeks, 6 months and I year. A number
of subgroups have been selected for particular analytic at-
tention, including patients treated within 2 hours of symp-
tom onset and those who present with ST segment elevation
in the anterior ECG leads.
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TIM/II Pi/or Study
Because the T1l\·11 II protocol is complicated and tech-
nically demanding, a pilot study, the TIMI H pilot displayed
in fig ure 2, was designed to determine feasibility and to
gather experience with the more diffi cult aspects of the TIMI
II protocol before initiating the randomized trial. At the
seven TIMI IIA clinical sites investigators began with rt-
PA followed by coronary angioplasty Il:l to 4l:l hours after
the initiation of rt-PA. After favorable administrative review
of angioplasty experience, these investigators proceeded to
treat patients with rt-PA followed by immediate coronary
arteriography and angioplasty within 120 minutes of initi-
ation of the rt-PA infusion. All patients entering the TIMT
II pilot at IIA sites were scheduled for predischarge cardiac
catheterization to assess feasibility, to determine the rate of
reocclusion and to assess global and regional left ventricular
function. During the pilot study. the TIMI liB clinical sites
performed the most demanding portion of the IIH protocol
which calls for immediate intravenous beta-blocker therapy
in those without contraindications and coronary arteriog-
raphy. followed by angioplasty, 18 to 4X hours after n-PA
treatment. A small number of patients were given rt-PA
without intention to perform lS to 48 hour coronary angio-
plusty in a numberof hospitals not approved for or interested
in performing angioplasty. These satellite hospitals trans-
ferred patients assigned to coronary angioplasty during TIMI
II to a central TIMI clinic with angioplasty capability.
Angioplast y certification rules. Because the outcome
of attempted coronary angioplasty is importantly related to
operator experience, and T1MI II patients are to he consid-
ered for dilation 18 to 48 hours after rt-PA or under even
more diffi cult circumstances (that is, < 120minutes after rt-
PA initiation in llA sites), the TIMI study group adopted
the following certification rules that were applied with rare
Figure 2. TIMI 1\ pilot design for 11 /\ and liB centers . Abbrc-
viations as in f igure I.
exception: I) All TIMI angioplasty operators must have
personally performed at least 100 cases with a <2% mor-
tality rate: and 2) the last 50 cases must have been done
with an l:l5% success rate.
Because coronary angioplasty at TIMI IIA sites is to be
performed at times during the acute phase of myocardial
infarction the following additional requirements had to be
met: I) The TIMI IIA angioplasty operators must have per-
sonally performed at least 200 cases and must have com-
pleted 20 cases with chronic total occlusion with a ~55%
succcsss rate: and 2) the TIMI IlA operator must have com-
pleted 20 cases in patients withacute infarction with a 2:.75%
success rate.
The major objective of the TIM! It pilot was to assess
the likelihood of performing successful coronary angioplasty
either immediately after or IS to 48 hours after the start of
rt-PA infusion. In addition, protocol adherence was assessed
at each center and in aggregate. In both the TIMI II and
pilot studies. all patients in both the immediate and delayed
coronary angioplasty groups were to undergo angioplusty
unless the contraindications to angioplasty detailed in Table
I were present.
Administration of rt-PA. Genentech, Inc supplied the
rt-PA (GI I044), prepared by a suspension culture fermen-
tation technique. that was used in the TIMI II pilot study
and in TIMI II. During most of the TIMI II pilot study a
dose of 150 mg infused over a 6 hour period was used. The
rt-PA infusion was begun expeditiously after patient selec-
tion and informed consent with a 9 rng bolus followed by
an Xl mg infusion over the fi rst hour, 20 mg in the second
hour and 10 mg in each of 4 additional hours. This dose
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was subsequently reduced to 100 mg over6 hours. including
a 6 mg holus followed by 54 mg in the first hour, 20 mg
in the second hour and 5 mg in each of 4 additional hours.
The dose reduction was effected shortly before completion
of the pilot study because of the occurrence of intracranial
hemorrhage (26). An additional 53 patients were treated in
the TIMI II pilot with the 100 mg dose; outcome in these
patients is discussed separately. The dose of rt-PA currently
being used in TlMI II is 100 mg over 6 hours in the same
hourly amounts discussed.
Results
TIM! II Pilot Study
Patient groups and features. A total of 317 patients
were treated with 150mg of rt-PA in the TIMI II pilot study
between March 17. 1986 and October 21. 1986. 253 patients
in the 18 to 48 hour coronary angioplasty group. 33 in the
immediate angioplasty group. and 31 were treated without
intention to do angioplasty at satellite hospitals where an-
gioplasty was not performed. One TIMI center withdrew
from further participation in the trial after having entered
nine patients. These nine patients were not included in the
TIMI II pilot analysis except for the une patient in this group
who developed intracranial hemorrhage. In addition. 53 pa-
tients (35 with intention to perform 18 to 48 hour angioplasty
and 18 with no intention to do angioplasty) were treated
with 100 mg rt-PA in the fi nal monthsof the TIMI II pilot.
The baseline features and arteriographic and clinical out-
come are presented for these five case series of patients
(Table 3). Random assignment was not used and therefore
comparisons among groups must be made judiciously. if at
Table 3. T IM I II Pilot Study: Baseline Character ist ics of 370 Patients
rt-PA Dose = 150 mg rt-PA Dose = 100 mg
Immediate 18 tn 48 Hour No PlCA 18 to 48 Hour Nil
PTCA PleA Group Group PlCA PTCA
(n = )3) (n = 253) (n = 31) (n = 35) (11 "- 18) Tota l
('7c) (%1 (qr) ('7e) (%) (n = 370)
Sex. male 87.9 79.0 77.4 77.1 77.8 78.9
Race. white 97.0 88.5 83 .9 97.1 100 .0 9(U
Not low risk 60 .6 73. 1 54 .8 74 .3 55 .6 69 .7
Age ~70 6. 1 14.2 3.2 11.4 16.7 12.4
Prior 1\·11 6. 1 1.1.8 3.2 22.9 5.6 12.7
Anterior MI 54 .6 55 .3 45.2 5 1.4 44.4 53 .8
Rales ~ '/. lung fields 3.0 4.7 0 .0 8.6 0 .0 4.3
Hypotension and sinus tachycardia 0 .0 5.9 6 .5 17.1 5.6 6.5
Atrial fibrillation or flutter 6.1 2.8 0 .0 0 .0 0 .0 2.4
Very high risk 3.0 20 0.0 8.6 0 .0 2.4
History of
Hypertension 48.5 32.4 25.8 40.0 38.9 34.3
Congestive heart failure 0.0 2.0 0.0 2.9 0 .0 2.4
Angina pectoris 39.4 53 .0 51.6 45.7 44.4 50 .5
Infarct-rela ted coronary artery
RCA 45.4 42 .3 50.0 43.5
LAD 45.4 48.6 34.4 46.7
LCx 6. 1 7.7 15.6 8.4
Normal coronary arteries 3.0 1.4 0 .0 1.4
(n = 33) (n = 220) (n = 32) (n = 285)
No. of vessels with ~70% stenosis
Zero 15.6 19.3 14.8 18.4
One 65 .6 55 .8 5 1.8 56 .6
Two 15 .6 22.8 25 .9 22.2
Three 3.t 2.0 7.4 2.7
(n .= 32) (n = 197) (n = 27) (n = 256)
Mean
Age (yr) 56 .8 56.9 55.7 55.9 56 .6 56 .7
Time from onset of chest pain 2. 1 1.4 1.0 1.1 1.3 1.4
to ER (h)
Onset to treatment (h) 3.0 2.7 2.6 2.6 2.6 2.7
Time from treatment to cath (h) 0 .9 31.8 33.1
Ejection fraction (%) 50 .7 49.7 51.0 49 .9
Cath = catheterization; ER = emergency room; LAD = left anterior descending; LCx = left circumflex coronary artery; MI = myocardial infarction;
PTCA = percutaneous translumin al coronary angioplasty: RCA = right coronary artery: rt-PA .= recombinant tissue-type plasminogen activator.
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all, particularly given the small sample size in the imme-
diate, the no angioplasty, and the 100 mg rt-PA groups.
Emergency room findings. TIMI II pilot patients are.
on average, middle-aged white men who arrived at an emer-
gency department I Ih to 2 hours after the onset of chest pain
(Table 3). A majority of the patients had one or more of
six risk factors for poor outcome, including anterior ST
segment elevation in >50%. Approximately one-half of
entering patients at TIMI lIB sites had one or more factors
that precluded immediate intravenous beta-blocker admin-
istration, including current treatment with a beta-blocker or
verapamil or diltiazem (21%), bradycardia (14%), hypo-
tension (11%), and left ventricular failure manifested by
pulmonary rales (8%). The interval between arrival in the
emergency department and initiation of rt-PA infusion av-
eraged slightly> I hour. A substantial portion of this delay
was due to discussion of the protocol and to obtaining in-
formed consent.
TIM! II Pilot Study: 18 to 48 Hour
Coronary Angioplasty
Cardiac catheterization findings (Fig. 3). A total of
253 patients entered the 18 to 48 hour coronary angioplasty
group and, thus, were scheduled for 18 to 48 hour cathe-
terization. Of these, 220 (87%) had catheterization Juring
this interval and 33 (13%) did not. Of these 33. 10 did not
have catheterization because of death or prior procedure, 4
because of prior hemorrhage, 12 because of protocol mis-
understandings and 7 becauseof patientor physicianrefusal.
TIMY grade 2 or 3 perfusion was noted in 192 (l:O%) of the
220 who did undergo catheterization and TIMI grade 0 or
I in 28 (Fig. 4). Left ventriculography in 176 patients re-
vcaled an average ejection fraction of 0.50. The infarct-
related artery was the right coronary artery in 93 (42(1'0) of
the 220 patients, the left anterior descending artery in 106
(48%) and the left circumflex coronary in 17 (8%). There
were an additional three patients with totally normal coro-
nary arteries. and one patient with left main coronary ste-
nosis. Using lesion severity of 2':70% reduction in luminal
diameter as a definition of significant disease, 110 (569'c)
of these 197 patients had single vessel disease. 45 (23%)
had double vessel disease and 4 (2%) had triple vessel dis-
ease, There were 38 patients (19%) who had no coronary
lesionsthat resulted in 2':70% reduction in luminal diameter.
In 23 patients the severity of coronary disease is not avail-
able.
Results of coronary angioplasty. The procedure was
attempted in 128 (58%) of 220 patients and resulted in
improvement in 123 (96%) (118 with full improvement and
5 with partial improvement), The reasons for not attempting
angioplasty included: infarct lesion stenosis <60 0k) in 37.
closed coronary artery in 27, technically impossible in 23
or not done for miscellaneous reasons in 5. There were no
procedure-related deaths; three patients had angioplasty-re-
lated coronary occlusion with myocardial necrosis and one
underwent emergency coronary bypass surgery within 24
hours of angioplasty. Thus, a total of 120 (94%) of 128
patients left the catheterization laboratory with an improved
infarct-related coronary lesion without complications in the
Flgure 3. Feasibility and outcome of coronary angioptasty (PTCA)
Ig to 4S hours after rt-PA infusion begun in 253 patients. CABG -r-
coronary artery bypass graft: CATH = catheterization: Ml =
myocardial infarction.
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next 24 hours. In aggregate, the strategy of rt-PA followed
by coronary arteriography and angioplasty, if possible, re-
sulted in 157 (62%) of 253 patients with known nonsignifi-
cant infarct-related lesions in the absence of complications
of coronary angiopJasty (37 with nonsignificant lesions plus
120 improved by angioplasty). In the first 72 hours, there
were eight deaths 0.2%) and 15 recurrent nonfatal infarc-
tions (5.9%), and 13 patients (5.1 %) underwent emergency
bypass surgery.
Hemorrhagic events. During the hospitalization, hem-
orrhagic events occurred in 123 (4~.69'0) of 253 patients and
hemorrhage sufficient to require transfusion occurred in 55
(22%). Transfusion during the course of coronary artery
bypass grafting was responsible for 23 of these transfusions
leaving the rate of nonsurgical transfusion at 13% (32 pa-
tients). Gastrointestinal bleeding was observed in 13patients
(5%).
Mortality and morbidity. At 21 days after study entry,
II of the 253 patients were dead (4.4%) and 22 (8.7%) had
had a clinically diagnosed recurrent nonfatal myocardial
infarction; 30 patients (12%) had had either a recurrent
infarction or had died (3 had nonfatal infarction followed
by death). This low 21 day mortality rate is most promising
in a relatively large sample in which 55% of patients had
anterior myocardial infarction and 13% had one or more of
six major risk factors. Furthermore, only two deaths oc-
curred in the interval between hospital discharge and 6 weeks
and only one recurrent infarction was noted. Thus at 6
weeks. the total mortality rate was 5.1%; the clinically di-
agnosed recurrent nonfatal infarction rate was 9.1%; and
Figure 4. Patency of infarct-related artery at arteriography per-
formed immediately (average I hour after start of rt-PA) and de-
layed 18 to 48 hours (average 32). solid bars = closed; open
bars = open; hatched bars = not done.
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13% of patients either had had recurrent infarction or had
died.
TIMI II Pilot Study: Immediate
Coronary Angioplasty
Cardiac catheterization findings (Fig. 4). Twenty-seven
(82%) of the 33 patients in this group had arteriographically
documented TIMI grade 2 or 3 coronary perfusion as read
by clinic investigators at first visualization of the infarct-
related artery an average of I hour after the initiation of rt-
PA infusion; the remaining six arteries were closed. Left
ventriculography revealed an average ejection fraction of
0.51. The infarct-relatedartery was the right coronary artery
in 15 (45%), the left anteriur descending in 15 (45%) and
the left circumflex in 2 patients (6%); I patient had normal
coronary anatomy. A total of 21 (66%) of the 32 patients
had one artery with a lesion resulting in a 2: 70% reduction
in luminaldiameter, 5 (16%) had two vessel disease, I (3o/c)
had three vessel disease and 5 (16%) had no vessel with
70% stenosis. The number of diseased vessels is unknown
for one patient.
Results of immediate angioplasty (Fig. 5). Twenty-
three (70%) of the 33 patients in this group underwent coro-
nary angioplasty an average uf I hour after the initiation of
rt-PA infusion, 18 (78%) with improvement (16 with full
improvement and 2 with partial improvement). In 10 (30%)
angioplasty was not attempted: 3 (9%) had an infarct-related
lesion that reduced luminal diameter <60%; 7 (21%) had
a lesion that was technically unsuitable. One death and three
coronary occlusions resulting in myocardial necrosis oc-
curred within 24 hours of coronary angioplasty, and no
patient underwent coronary bypass surgery within 24 hours
of attempted angioplasty. Thus, in 23 patients in whom
angioplasty was performed, 16(70%) left the catheterization
laboratory with a <60% stenotic lesion and survived the
next 24 hours free of recurrent infarction and need for emer-
gency coronary bypass surgery. In aggregate, the strategy
of rt-PA followed by immediate coronary angioplasty re-
sulted in 19 (5R%) of 33 patients with a known nonsignifi-
cant infarct-related lesion in the absence of coronary an-
gioplasty-relatcd complications within 24 hours of the
procedure (3 with a nonsignificant lesion and 16 with im-
provement after angioplasty). At 72 hours, there were no
additional deaths or recurrent infarctions. and there were no
instances of unplanned coronary angioplasty or emergency
coronary artery bypass graft surgery.
Hemorrhagic events. These were reported in 13 (39o/e)
of the 33 patients; transfusions were given in 7 (21%), and
in 3 of these 7 they were given during the course of coronary
bypass surgery. Gastrointestinal bleeding was observed in
3 (9%) of these 33 patients. Coronary artery bypass graft
surgery was performed in 3 (9%) during hospitalization.
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· .Figure 5. Feasibility and outcome of coronary
angioplasty (PTCA) immediately after rt-PA in-
fusion begun in JJ patients. Abbreviations as in
Figure 3.
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Postangioplasty catheterization. All 33 patients treated
with rt-PA and the intention to carry out immediate coronary
angioplasty were scheduled for cardiac catheterization S to
10 days after treatment. and 22 patients (67%) actually
completed this study. Included in these 22 wen: J3 of the
18 who had had an improved lesion after immediate angie-
plusty; in 12 (92%) of the 13 the infarct-related artery re-
mained patent Among the 10 patients who did not undergo
immediate angioplasty, there were 7 who underwent angi-
ography at S to 10 days. and in 6 (86%) the infarct-related
artery was patent. The reasons for failure to comply with
the 8 to 10 day catheterization included three deaths, coro-
nilry artery bypass graft in two and refusal by the patient
or attending physician in the remaining six.
Postangioplasty death or infarction. By 21 days after
study entry (9. 1% ) of the 33 patients with immediate an-
gioplasty were dead. 7 (21% ) had had a clinically diagnosed
rCCUITent myocardial infarction. so that 10 (30% ) either had
died or had had a recurrent nonfatal infarction. At 6 weeks
there were no additional deaths or recurrent myocardial in-
farctions in the 30 patients who were alive at 21 days .
TIMI /I Pilot Study: No Coronary Angioplasty
In 3 1 patients in this group. rt-PA was given in a 150
mg dose without intention to perform coronary angioplasty.
By 72 hours there were no deaths. three (9.70/1-.) clinically
diagnosed recurrent infarctions, three (9.7%) instances of
unplanned coronary angioplasty and no coronary artery by-
pass graft surgery. Before 2 1 days, there were no deaths.
and five ( 16%) recurrent infarctions were noted: no addi-
tional deaths or infarctions were noted before 6 weeks.
Hemorrhage sufficient to require transfusion occurred in two
patients (6.5%). By 6 weeks, there were no additional deaths
and no recurrent infarctions in those alive at 2 1 days.
TIMIII Pilot Study: 100 mK rt-PA
The dose of rt-PA used in the T1MI II pilot study was
reduced just before completion. A total of 53 patients were
treated with the JOO mg dose of rt-PA after this protocol
change and no instances of intracranial hemorrhage were
noted. The patency rate at IS to 48 hours in 32 patients
undergoing catheterization as a prelude to coronary angie-
plasty was XX%. Angioplasty was attempted in IY patients
(59.4%) and resulted in improvement in 17 (89%). By 72
hours. there had been 4 deaths (7.5%) in the 53 patients.
and no patient had had a recurrent myocardial infarction:
there was no coronary bypass surgery during this interval.
Hemorrhagic events sufficient to require transfusion oc-
curred in 5 (9.4%). At 21 days atter study entry, there were
no additional deaths, and 3 (5.7 %) of the 53 patients had
a clinically diagnosed recurrent nonfatal infarction. At 6
weeks, there were no additional deaths and two recurrent
infarctions in those alive at 21 days.
Mortality and Survival Free of Recurrent lnja rction
in TIMI /I Pilot Study
Mortality and recurrent infarction. In all 3 17 patients
in the TIMI II pilot study treated with 150 mg rt-PA who
presented to TIMl centers < 4 hours after the onset of pain,
the () week rate of mortality or clinically diagnosed recurrent
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Table 4. Occurrence of Clinica l Events in 3 17 TlM[ II Pilot Patients Who Received [50 mg of Recom binant Tissue-Type
Plasminogen Activator
2 Hours 18 to 48 Hours No PTCA Total
no. % no. % no. 'le no. %
Patients 33 253 3 1 317
Transfusion 7 21.2 54 21.3 2. 6.5 63 19.9
Ie hemorrhage 0 0 4 1.6 0 0 4 1.2
Cumulative mortality <days)
3 I 3.0 8 3.2 0 0 9 2.8
14 3 9.1 II 4.4 0 0 14 4.4
2 1 3 9 . 1 II 4.4 0 0 14 4.4
42 3 9 .1 13 5 .1 0 0 16 5.0
Cumulative nonfatal MI (days)
3 3 9.1 15 5.9 3 9.7 2 1 6 .6
14 7 21.2 21 8 .3 5 16.1 33 10.4
2 1 7 21.2 22 8.7 5 16.1 34 10.7
42 7 21.2 23 9. 1 5 16. 1 35 11.0
Cumulative mortality or nonfatal MI (days)
3 4 12.1 22 lU 3 9.7 29 9 . 1
14 10 30.3 29 11.5 5 16.1 44 13.9
2 1 10 30.3 30 11.9 5 16. 1 45 14.2
42 10 30.3 33 13.0 5 16.1 48 15. 1
Ie = intracranial; other abbreviations as in Table 3.
nonfatal myocardial infarction was 15% (16 deaths and 35
nonfatal myocardial infarctions). Of 75 patients who were
given rt-PA within 2 hOUfS of onset of chest pain. only 2
(3%) failed to survive to 6 weeks. Bothentered with anterior
ST segment elevation; one was in shock at initiation of rt-
PA infusion and died in the catheterization laboratory sev-
eral hours later of ventricular arrhythmia after attempts to
open a closed left anterior descending artery and to reverse
the shock had failed. The other had had rcinfarction after
cessation of the rt-PA infusion and had subsequently under-
gone successful coronary bypass surgery but died postop-
eratively of ventricular arrhythmia during the second hos-
pital day. In 242 patients treated between 2 and 4 hours
after the onset of chest pain. the 6 week mortality rate was
6%.
In 172 patients who entered with anterior ST elevation
and 145 patients with inferior ST elevation, the 6 week
mortal ity rate was virtually identical at 4.7 and 5.5%. re-
spectively, a rather surprising similarity given the expected
higher rate for anterior myocardial infarction (9).
Intracerebral hemorrhage (Appendix 2). There were
four instances of intracerebral hemorrhage in the 317 pa-
tients who received 150 mg rt-PA. One additional patient.
among the nine treated at the TIMI clinic that subsequently
withdrew from the study, had an intracranial hemorrhage.
Thus. a total of 5 patients had intracranial hemorrhage among
the total of 326 treated with 150 mg of rt-PA in the TL\1I
II pilot study. Three of the five episodes occurred during
the first 24 hours and three were fatal. The intervalsbetween
initiation of rt-PA and heparin and the onset of neurologic
deficit were 5t 6, 20. 24 and 72 hours, respectively, in the
five cases. The two surviving patients were left with a neu-
rologic deficit. One patient gave a historyof stroke 15years
before the present illness and another a history compatible
with recent transient ischemic attacks. Brief summaries of
these cases are provided in Appendix 2. No instance of
intracerebral hemorrhage occurred in the 53 patients treated
in the TIMI II pilot with lOO mg rt-PA.
Discussion
Success rate of early coronary angioplasty. In TIMI
II pilot patients, 82 and 87% of infarct-related arteries were
patent when studied an average of 1 or 32 hours after ini-
tiation of rt-PA infusion. In the immediate coronary angio-
plasty group. all treated with 150 mg. and in the 150 and
100 mg 18 to 48 hour angioplasty groups. 9. 17 and 16%.
respectively. had < 60% coronary obstruction when studied
and thus were not eligible for angioplasty. Among patients
catheterized within 2 hours of initiation of rt-PA infusion,
approximately two-thirds had coronary anatomy that per-
mitted angioplasty and in approximately 70% of those. the
infarct-related artery was successfully dilated without com-
plications. In those studied at 18 to 48 hours. three-fi fths
had coronary anatomysuitable for angioplasty and in nearly
all the infarct artery was successfully dilated. In TIMI II
pilot patients. particularly those treated at 18 to 48 hours,
angioplasty carried an immediate risk not greatly different
from that of angioplasty in chronic coronary artery disease.
This is probably the result of limiting angioplasty to ex-
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pcrienced operators. and to careful standardization of se-
lection of candidates for angioplasty: both arc major factors
in success rates for angioplasty.
Mortality. The numbers of patients in the immediate
coronary angioplasty group, the no coronary angioplasty
group and the 100 mg rt-PA group are small. and thus
estimates of the true event rates are quite unstable. In con-
trast. the 150 mg rt-PA 18 to 48 hour angioplasty group is
large enough to provide end point estimates with less var-
iability. The 21 day and 6 week mortality rates in these
patients are low and consistent with interruption of the in-
farction process by the early intravenous administration of
an effective thrombolytic agent.
In all patients treated within 2 hours of onset of infarction,
of whom 70S{ had anterior infarction. the mortality is very
low. Previous reports have documented that patients with
anterior myocardial infarction face a risk of mortality during
the hospital course several times that of patients with non-
anterior infarction (9 and unpublished data). This difference
in mortality was effaced in TIMI II pilot study patients. a
finding that lends credence to the tenet that rt·PA may reduce
mortality in addition to effecting reperfusion.
Intracranial hemorrhage and stroke. The occurrence
of stroke in the wake of acute myocardial infarction has
been reported at a rate of I to 2ck. Embolism from left
ventricular mural thrombi is the presumed mechanism. The
rate of hemorrhagic stroke reported in recent thrombolytic
trials (8-12 and unpublished data) using streptokinase ranges
from 5 to 1011 .000. The rate of intracranial hemorrhage in
the TIMll! pilot study was similar. 5 (1.5"'k.1 in 326 patients
and this is surprising given the paucity of intracranial hem-
orrhage in prior TlMI studies of rt-PA (I in 3/1t)). It is likely
that there is a small group of patients with myocardial in-
farction whose cerebral vasculature is unequal to the chal-
lenge of 150 rng of rt-PA followed hy vigorous anticoag-
ulation with heparin. Patients with a history of stroke or
poorly controlled hypertension. or both. seem at risk ami
should receive thrombolytic therapy for myocardial infarc-
tion only after careful explicit analysis of risk/benefit ratio
for the individual patient. In view of this rate of intracranial
hemorrhage and the similarity in 90 minute repcrfusion rates
documented in prior TIMI studies in patients receiving 150
and 100 rug (19), the Jose used in the last 53 pilot study
patients was 100 rug given over 6 hours. There was no
intracranial hemorrhage in these patients. This is the Jose
now used in the TIMl 11 study.
The early identification of candidates for thrombolytic
therapy. This is fundamental to the success of this thera-
peutic approach because the quantity of salvaged myocar-
dium drops rapidly with (he passage of lime: little myocar-
dium is spared beyond 4 to 6 hours. However. the risk of
bleeding probably does not change appreciably over time
after the onset of infarction. Thus, the benefit/risk ratio of
this form of therapy fallsquickly with the passage of minutes
and hours after the onset of infarction and represents the
major impediment to successful application.
Conclusion. The TIMI II pilot study has revealed that
the TIMIII protocol is feasible. The rates of coronary artery
patency are high (80 to 909C); mortality rates are low overall
and very low in patients treated within 2 hours and in patients
with anterior wall myocardial infarction. The 1.5c!c inci-
dence rate of intracranial hemorrhage led to a reduction in
rt-PA dose from 150 to 100 mg. The TIMI investigators are
proceeding to test by means of a formal randomized trial
the advisability of adding immediate intravenous beta-re-
ceptor blocker therapy to rt-PA and of performing coronary
angioplasty in patients with acute myocardial infarction treated
with rt-PA <4 hours after the onset of chest pain.
TIMI Phase II Pilot
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Appendix 2
TIMI II Pilot Study
Five patients experienced intracerebral hemorrhage in the course of a
TIMI " pilot study.
Case 1. A 69 year old man presented with 90 minutes of substernal
pain and electrocardiographic (ECm abnormalities consistent with acute
inferior wall myocardial infarction. There was no history of hypertension,
but the patient had a history of prim myocardial infarction. Although
neurologic abnormalities were denied at presentat ion. the patient 's family
later confirmed thut he had experienced transient episodes of left-sided
weakness and numbness. Seventy-three minutes after completion of a 6
hour infusion of ISO mg rt-PA the patient developed left hand and leg
weakness thai progressed til left ham! paralysis. A computer axial tomog -
raphy (CAT) scan did not find any intracerebral hemmorhage. Heparin
therapy was restarted . Twelve hours later the patient displayed slurred
speech and a profound left hemiparesis. Repeat CAT scan revealed a large
parenchymal hcmatoma in the region of the right basal ganglia. Despite a
ventriculostomy. the patient remained unresponsive and died on the third
day after study entry.
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Case 2. A 62 year old man presented with 60 minutes of substernal
chest pain and ECG abnormalities consistent with an acute anterior wall
myocardial infarction. He had a history of chronic. therapeutically con-
trolled hypertension and of myoclonic jerking treated with phenobarbital.
Despite a 6 hour infusion of 150 mg rt-PA. beta-receptor blocker therapy.
nitroglycerin infusion and antiarrhythmic therapy with bretylium, his chest
pain never abated. An intraaortic balloon pump was instituted for man-
agement of hypotension and arrhythmias. Late in the day of study entry.
the patient's mental status deteriorated. and he was placed on a ventilator.
Three days later this patient was heavily sedated for agitation and direct
current cardioversion was performed for rapid atrial libnllation. After car-
dioversion, he was found to have no spontaneous movement of his left
arm or leg. A CAT scan revealed parenchymal hemorrhage with ventricular
dissection. After ventriculostomy. the patient experienced a complicated
course with lengthy periods of mechanical ventilation. pneumonia and
death 9 weeks after study entry.
Case 3. A 52 year old man presented with 80 minutes of chest pain
and ECG abnormalities consistent with acute anterior wall myocardial
infarction and Wolff-Parkinson-White conduction defect. He had a prc-
vious history of hypertension and angina treated with beta-receptor block-
ers. He also reported frequent headaches and a remote history of light-
headedness, tremor and palpitation. He complained of a slight headache
51 hours after starting thrombolytic therapy. An hour later the headache
was Improved with acetaminophen. After another hour he was sweaty and
short of breath and produced guaiac-negative emesis. Shortly thereafter.
he said his headache felt better, but he displayed nuchal rigidity. As nuchal
rigidity worsened. he complained of severe headache. but a CAT scan
found no evidence of intracerebral blood. Fourteen hours after study entry
he was unresponsive. with a blood pressure of 2061106 mm Hg, stridor.
constricted pupils and bilateral Babinski sign. A CAT scan identified left
occipital hematoma. At craniotomy a right intracerebellar hematoma was
evacuated and the patient has shown steady neurologic improvement. At
hospital discharge, 4 weeks after study entry, he was still affected by ataxia
and tremor.
Case 4. A 67 year old woman presented with 120 minutes of substernal
pain and ECG abnormalities consistent with acute anterior wall mvocardial
infarction. She had a history of hypertension and angma treated with
diuretics, beta-blockers and calcium channel blockers. She had had a cere·
brovascular accident 15years before presentation. One day after completion
of a 6-hour infusion of 150 mg rt-PA she experienced ~astrojnkstinal
hemorrhage and hemorrhage at the site of catheterizanon fur coronary
angioplasty. These were treated with multiple transfusions and surgical
repair of the common femoral artery. Forty-eight hours after study entry.
she experienced a focal seizure: a CAT scan revealed hemorrhage near the
occipital ventricle. Her course was further complicated by multiple in-
traarterial thromboses, acute renal failure and respiratory failure. She died
II days after study entry.
Case 5. A 66 year old woman presented with 2 hours of substernal
pain and ECG abnormalities consistent with acute inferior wall myocardial
infarction. She had a history or mastectomy for carcinoma of the breast;
one dissected lymph node showed malignancy. and the pauent had received
a year of chemotherapy. She had no history of hypertension or neurologic
disorder. Fourteen huur-, after completion of a 6 hour infusion III 150 mg
rt-PA the patient experienced a generalized tonic-clonic seizure followed
by apnea and ventricular tachycardia. She was succcssfully resuscitated
A CAT scan showed a left frontoparietal hemorrhage. Her neurologic statu.
slowly but steadily improved. She was discharged n weeks after study
entry suffering from right arm and leg paresis. anomia, aphasia and memory
loss.
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